MaxCyte Future Growth
Future criteria checks 2/6
MaxCyte is forecast to grow earnings and revenue by 3.3% and 20.5% per annum respectively. EPS is expected to grow by 3.8% per annum. Return on equity is forecast to be -14.5% in 3 years.
Key information
3.3%
Earnings growth rate
3.8%
EPS growth rate
| Life Sciences earnings growth | 26.2% |
| Revenue growth rate | 20.5% |
| Future return on equity | -14.5% |
| Analyst coverage | Good |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 60 | -33 | -45 | N/A | 5 |
| 12/31/2025 | 46 | -41 | -50 | N/A | 8 |
| 12/31/2024 | 38 | -43 | -52 | N/A | 7 |
| 9/30/2024 | 46 | -36 | -21 | -19 | N/A |
| 6/30/2024 | 45 | -35 | -25 | -23 | N/A |
| 3/31/2024 | 44 | -37 | -31 | -28 | N/A |
| 12/31/2023 | 41 | -38 | -25 | -22 | N/A |
| 9/30/2023 | 38 | -37 | -34 | -29 | N/A |
| 6/30/2023 | 41 | -33 | -34 | -26 | N/A |
| 3/31/2023 | 41 | -30 | -29 | -15 | N/A |
| 12/31/2022 | 44 | -24 | -33 | -15 | N/A |
| 9/30/2022 | 42 | -24 | -27 | -10 | N/A |
| 6/30/2022 | 41 | -20 | -20 | -4 | N/A |
| 3/31/2022 | 39 | -16 | -19 | -10 | N/A |
| 12/31/2021 | 34 | -19 | -15 | -11 | N/A |
| 9/30/2021 | 32 | -17 | -15 | -12 | N/A |
| 6/30/2021 | 29 | -17 | -14 | -12 | N/A |
| 3/31/2021 | 27 | -16 | -10 | -8 | N/A |
| 12/31/2020 | 26 | -12 | -11 | -9 | N/A |
| 9/30/2020 | 24 | -11 | -10 | -8 | N/A |
| 6/30/2020 | 24 | -9 | -10 | -8 | N/A |
| 3/31/2020 | 23 | -11 | -13 | -11 | N/A |
| 12/31/2019 | 22 | -13 | -10 | -9 | N/A |
| 9/30/2019 | 20 | -13 | -11 | -10 | N/A |
| 6/30/2019 | 18 | -14 | -11 | -10 | N/A |
| 3/31/2019 | 17 | -11 | -11 | -10 | N/A |
| 12/31/2018 | 17 | -9 | -11 | -10 | N/A |
| 9/30/2018 | 16 | -10 | -11 | -11 | N/A |
| 6/30/2018 | 15 | -10 | N/A | -11 | N/A |
| 3/31/2018 | 14 | -10 | N/A | -10 | N/A |
| 12/31/2017 | 14 | -10 | N/A | -10 | N/A |
| 9/30/2017 | 13 | -8 | N/A | -8 | N/A |
| 6/30/2017 | 13 | -6 | N/A | -6 | N/A |
| 3/31/2017 | 13 | -5 | N/A | -4 | N/A |
| 12/31/2016 | 12 | -4 | N/A | -2 | N/A |
| 9/30/2016 | 11 | -4 | N/A | -2 | N/A |
| 6/30/2016 | 11 | -3 | N/A | -2 | N/A |
| 3/31/2016 | 10 | -3 | N/A | -1 | N/A |
| 12/31/2015 | 9 | -4 | N/A | 0 | N/A |
| 9/30/2015 | 9 | -4 | N/A | 0 | N/A |
| 6/30/2015 | 8 | -4 | N/A | 0 | N/A |
| 3/31/2015 | 8 | -4 | N/A | -1 | N/A |
| 12/31/2014 | 7 | -4 | N/A | -2 | N/A |
| 12/31/2013 | 7 | -3 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYE0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MYE0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MYE0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MYE0's revenue (20.5% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: MYE0's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYE0 is forecast to be unprofitable in 3 years.